MicroRNA-16逆转上皮性卵巢癌耐药的动物实验研究Reversal of cisplatin-resistance in human ovarian cancer xenograft model by microRNA-16 in nude mice
韩汶君;崔竹梅;唐蕊;于沙沙;娄艳辉;高慧;
摘要(Abstract)：
目的:研究微小RNA-16(miR-16)对人上皮性卵巢癌裸鼠皮下移植瘤耐药性的逆转作用,并初步探讨其逆转作用机制。方法:24只BALB/c裸鼠,随机分为四组,每组6只:Ⅰ组给予皮下接种卵巢癌SKOV3细胞株,成瘤后应用顺铂治疗;Ⅱ组皮下接种卵巢癌SKOV3/DDP顺铂耐药细胞株,成瘤后给予顺铂治疗;Ⅲ组皮下接种卵巢癌SK-OV3/DDP顺铂耐药细胞株,成瘤后给予顺铂与miR-16阴性对照试剂(miR-16 Negative)协同治疗;Ⅳ组接种卵巢癌SKOV3/DDP顺铂耐药细胞株,成瘤后给予顺铂与miR-16化学修饰模拟物(miR-16 Agomir)协同治疗。观察比较四组皮下肿瘤生长情况,种瘤后第35天处死裸鼠,称取肿瘤组织质量,逆转录-聚合酶链反应(RT-PCR)方法检测肿瘤组织中bcl-2 mRNA表达,免疫组化方法检测各组肿瘤组织中bcl-2蛋白表达。结果:顺铂与miR-16 Agomir协同治疗组裸鼠皮下肿瘤生长受到明显抑制,其肿瘤组织中bcl-2 mRNA表达水平较其余各组降低,差异具有显著性(P<0.05),其bcl-2蛋白表达亦明显低于其余各组(P<0.05)。结论:miRNA-16可能通过对其靶基因bcl-2的反向调控作用,逆转裸鼠卵巢癌皮下移植瘤顺铂耐药性。
关键词(KeyWords)： 微小RNAs;卵巢肿瘤;基因,bcl-2;小鼠;移植;基因疗法;顺铂
基金项目(Foundation):
作者(Authors): 韩汶君;崔竹梅;唐蕊;于沙沙;娄艳辉;高慧;
DOI: 10.13283/j.cnki.xdfckjz.2012.10.023
参考文献(References)：
- [1]Stronach EA,Chen M,Maginn EN,et al.DNA-PK medi-ates AKT activation and apoptosis inhibition in clinicallyacquired platinum resistance[J].Neoplasia,2011,13(11):1069-1080
- [2]Weeraratne SD,Amani V,Neiss A,et al.miR-34a conferschemosensitivity through modulation of MAGE-A and p53in medulloblastoma[J].Neuro Oncol,2011,13(2):165-175
- [3]Xia L,Zhang D,Du R,et al.miR-15b and miR-16 modu-late multidrug resistance by targeting bcl-2 in human gas-tric cancer cells[J].Int J Cancer,2008,123(2):372-379
- [4]Wang CJ,Zhou ZG,Holmqvist A,et al.Survivin expres-sion quantified by Image Pro-Plus compared with visualassessment[J].Appl Immunohistochem Mol Morphol,2009,17(6):530-535
- [5]Yan X,Yin J,Yao H,et al.Increased expression of annex-in A3 is a mechanism of platinum resistance in ovariancancer[J].Cancer Res,2010,70(4):1616-1624
- [6]Low SY,Tan BS,Choo HL,et al.Suppression of BCL-2synergizes cisplatin sensitivity in nasopharyngeal carcino-ma cells[J].Cancer Lett,2012,314(2):166-175
- [7]Wang J,Zhou JY,Zhang L,et al.Involvement of MKP-1and bcl-2 in acquired cisplatin resistance in ovarian canc-er cells[J].Cell Cycle,2009,8(19):3191-3198
- [8]Bhattacharya R,Nicoloso M,Arvizo R,et al.MiR-15a andMiR-16 control Bmi-1 expression in ovarian cancer[J].Cancer Res,2011,69(23):9090-9095
- [9]Kim CH,Kim HK,Retting RL,et al.miRNA signature as-sociated with outcome of gastric cancer patients followingchemotherapy[J].BMC Med Genomics,2011,4(11):79-81
- [10]李有杰,孙强,岳真,等.顺铂致A549细胞miR-16与bcl-2表达的变化[J].肿瘤防治研究,2011,38(11):1224-1227